abrdn plc Raises Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

abrdn plc grew its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 158.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 326,995 shares of the biopharmaceutical company's stock after buying an additional 200,647 shares during the quarter. abrdn plc owned 0.80% of Abeona Therapeutics worth $2,067,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Rosalind Advisors Inc. purchased a new stake in shares of Abeona Therapeutics during the second quarter worth about $7,420,000. Western Standard LLC lifted its holdings in Abeona Therapeutics by 68.5% in the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock worth $9,871,000 after buying an additional 553,377 shares during the period. Renaissance Technologies LLC grew its position in shares of Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock worth $2,134,000 after buying an additional 429,456 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $1,732,000. Finally, Acadian Asset Management LLC bought a new position in shares of Abeona Therapeutics during the first quarter valued at approximately $91,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Stock Up 2.8 %

Shares of Abeona Therapeutics stock traded up $0.17 during trading on Tuesday, hitting $6.21. The company's stock had a trading volume of 193,090 shares, compared to its average volume of 434,636. Abeona Therapeutics Inc has a 52 week low of $3.05 and a 52 week high of $9.01. The company has a market capitalization of $268.98 million, a PE ratio of -2.43 and a beta of 1.52. The company has a fifty day simple moving average of $6.06 and a two-hundred day simple moving average of $5.13. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.42). Equities research analysts predict that Abeona Therapeutics Inc will post -1.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ABEO. Cantor Fitzgerald reissued an "overweight" rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, September 10th. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Abeona Therapeutics in a report on Thursday, October 31st.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.